Acute Coronary Syndromes require treatment with multiple drugs which reduce blood clotting to prevent recurrent ischemia. However, this is attained at a cost of mild increase in bleeding episodes.

Here we report the findings of a new study which assessed whether fondaparinux would preserve the anti-ischemic benefits of the low molecular weight heparin, enoxaparin, while reducing bleeding. Fondaprinux is direct thrombin inhibitor.

Results of the study showed that Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days in patients with acute coronary syndromes, but it substantially reduces major bleeding and improves long term mortality and morbidity.

The full study will be published in NEJM on April 6th.

Abstract link